2025
Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis
Chow R, Basu A, Kaur J, Hui D, Im J, Prsic E, Boldt G, Lock M, Eng L, Ng T, Zimmermann C, Scotte F. Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis. Supportive Care In Cancer 2025, 33: 193. PMID: 39953210, PMCID: PMC11828838, DOI: 10.1007/s00520-025-09251-w.Peer-Reviewed Original ResearchMeSH KeywordsAntiemeticsAntineoplastic AgentsCannabinoidsHumansNauseaNeoplasmsRandomized Controlled Trials as TopicVomitingConceptsChemotherapy-induced nausea and vomitingEfficacy of cannabinoidsTHC:CBDMeta-analysisPrevention of chemotherapy-induced nausea and vomitingProphylaxis of chemotherapy-induced nausea and vomitingChemotherapy-induced nausea and vomiting controlControlled TrialsCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsRegister of Controlled TrialsNausea and vomitingChemotherapy-induced nauseaMethodsA literature searchCochrane Central RegisterComplete responseRandomized Controlled TrialsNo vomitingAdjunctive therapyRescue medicationAntiemetic regimensComposite endpointSubgroup analysisCannabinoidSecondary preventionNav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids
Ghovanloo M, Tyagi S, Zhao P, Waxman S. Nav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2416886122. PMID: 39835903, PMCID: PMC11789019, DOI: 10.1073/pnas.2416886122.Peer-Reviewed Original ResearchConceptsExcitation of peripheral sensory neuronsTherapeutic potential of cannabinoidsPotential of cannabinoidsPeripheral sensory neuronsVoltage-gated sodiumSpectrum of adverse effectsNociceptor excitabilityPain signalsIn vivo studiesAnalgesic targetsPain treatmentAttenuate painRepetitive firingNav1.8Sensory neuronsTreatment optionsClinical studiesInhibit excitabilityAnalgesic compoundsPainTherapeutic potentialCannabigerolProof-of-principalAdverse effectsTreatment
2023
Dysregulation of the endogenous cannabinoid system following opioid exposure
Mohammad Aghaei A, Saali A, Canas M, Weleff J, D'Souza D, Angarita G, Bassir Nia A. Dysregulation of the endogenous cannabinoid system following opioid exposure. Psychiatry Research 2023, 330: 115586. PMID: 37931479, PMCID: PMC10842415, DOI: 10.1016/j.psychres.2023.115586.Peer-Reviewed Original ResearchConceptsEndocannabinoid systemECS componentsBrain regionsNovel neurobiological targetsTreatment of OUDEndogenous opioid systemOpioid-related deathsEndogenous cannabinoid systemSpecific brain regionsECS dysregulationOpioid exposureOUD treatmentOpioid systemCannabinoid systemNeurobiological targetsNew medicationsPreclinical literatureCannabinoid receptorsEndogenous ligandTherapeutic potentialStudy typePresent potential targetsExposure protocolOpioidsPreclinical researchAddiction Medicine Physicians and Medicinal Cannabinoids
Potenza M, Bunt G, Khalsa J. Addiction Medicine Physicians and Medicinal Cannabinoids. JAMA Psychiatry 2023, 80: 659-660. PMID: 37133830, DOI: 10.1001/jamapsychiatry.2023.0731.Commentaries, Editorials and LettersCannabis positivity rates in 17 emergency departments across the United States with varying degrees of marijuana legalization
Tolan N, Krasowski M, Mathias P, Wiencek J, Babic N, Chai P, Chambliss A, Choucair I, Demetriou C, Erickson T, Feldhammer M, French D, Hayes B, Kang P, El-Khoury J, Knezevic C, Monte A, Nerenz R, Okorodudu A, Roper S, Saitman A, Thiriveedhi V, Uljon S, Vest A, Woodworth A, Yu M, Melanson S. Cannabis positivity rates in 17 emergency departments across the United States with varying degrees of marijuana legalization. Journal Of Toxicology Clinical Toxicology 2023, 61: 248-259. PMID: 37129223, PMCID: PMC10793079, DOI: 10.1080/15563650.2023.2177552.Peer-Reviewed Original ResearchCannabinoid regulation of neurons in the dentate gyrus during epileptogenesis: Role of CB1R‐associated proteins and downstream pathways
Lafourcade C, Sparks F, Bordey A, Wyneken U, Mohammadi M. Cannabinoid regulation of neurons in the dentate gyrus during epileptogenesis: Role of CB1R‐associated proteins and downstream pathways. Epilepsia 2023, 64: 1432-1443. PMID: 36869624, DOI: 10.1111/epi.17569.Peer-Reviewed Original ResearchConceptsTemporal lobe epilepsyDentate gyrusStatus epilepticusProgression of epileptogenesisHippocampal dentate gyrusRole of CB1RCannabinoid regulationHippocampal excitabilityRecurrent seizuresLobe epilepsyRecent findingsEndogenous cannabinoidsBrain injuryClinical trialsEpileptic dischargesNeurologic disordersRetrograde messengerDG circuitryHippocampal formationNeuronal activityTherapeutic interventionsSeizuresEpileptogenesisExcessive excitationCannabinoids
2022
The Relationship Between Cannabinoids and Neural Oscillations: How Cannabis Disrupts Sensation, Perception, and Cognition
Syed S, Martin A, Cortes-Briones J, Skosnik P. The Relationship Between Cannabinoids and Neural Oscillations: How Cannabis Disrupts Sensation, Perception, and Cognition. Clinical EEG And Neuroscience 2022, 54: 359-369. PMID: 36426543, DOI: 10.1177/15500594221138280.Peer-Reviewed Original ResearchConceptsNeural oscillationsNeural synchronyImportant clinical implicationsExcitatory balanceTheta frequency rangeClinical studiesClinical implicationsNeural circuitsCannabis useBrain functionOscillatory disruptionsNeural activityCannabinoidsSensationPotential relationshipCritical mechanismElectroencephalographyDisruptionSchizophreniaAlleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies
De Aquino J, Bahji A, Gómez O, Sofuoglu M. Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. Drug And Alcohol Dependence 2022, 241: 109702. PMID: 36434879, PMCID: PMC9772106, DOI: 10.1016/j.drugalcdep.2022.109702.Peer-Reviewed Original ResearchConceptsOpioid withdrawalObservational studySystematic reviewDelta-9-tetrahydrocannabinol administrationPlacebo-controlled clinical trialCannabis useNon-opioid therapeuticsPotential of cannabinoidsDose of opioidsOpioid withdrawal symptomsOpioid use disorderNarrow therapeutic windowExperimental human studiesDose-dependent increaseMain psychoactive constituentPatient characteristicsWithdrawal symptomsClinical trialsPharmacological factorsStudy qualityTherapeutic windowTherapeutic benefitUse disordersHuman studiesAbuse liabilityCannabinoids and solid organ transplantation: Psychiatric perspectives and recommendations
Winder GS, Andrews SR, Banerjee AG, Hussain F, Ivkovic A, Kuntz K, Omary L, Shenoy A, Thant T, VandenBerg A, Zimbrean P. Cannabinoids and solid organ transplantation: Psychiatric perspectives and recommendations. Transplantation Reviews 2022, 36: 100715. PMID: 35853383, DOI: 10.1016/j.trre.2022.100715.Peer-Reviewed Original ResearchConceptsSolid organ transplantationCannabinoid useOrgan transplantationClinical careUS transplantation centersSOT patientsKidney transplantationTransplantation centersCannabinoid effectsClinical impactClinicians' perceptionsMedical literaturePatientsTransplantationCliniciansCannabinoidsCareInterprofessional issuesPsychiatric perspectiveFuture studiesUse ratesProfessional societiesSystematized reviewOngoing dilemmaRecommendationsInhibition of sodium conductance by cannabigerol contributes to a reduction of dorsal root ganglion neuron excitability
Ghovanloo M, Estacion M, Higerd‐Rusli G, Zhao P, Dib‐Hajj S, Waxman SG. Inhibition of sodium conductance by cannabigerol contributes to a reduction of dorsal root ganglion neuron excitability. British Journal Of Pharmacology 2022, 179: 4010-4030. PMID: 35297036, DOI: 10.1111/bph.15833.Peer-Reviewed Original ResearchConceptsEffect of cannabigerolDRG neuronsDorsal root ganglion neuron excitabilityVoltage-gated sodium currentDorsal root ganglion neuronsLower CBG concentrationPrimary dorsal root ganglion neuronsAnalgesic drug developmentNon-psychotropic phytocannabinoidMultielectrode array recordingsAction potential modellingInhibition of NaDRG excitabilityGanglion neuronsNeuron excitabilityAnalgesic propertiesCNS neuronsNeuronal hypoexcitabilityCBG concentrationsChannel inhibitorsSodium currentNeuronsFunctional selectivityDrug developmentUnderlying mechanismConsensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis
D’Souza D, DiForti M, Ganesh S, George TP, Hall W, Hjorthøj C, Howes O, Keshavan M, Murray RM, Nguyen TB, Pearlson GD, Ranganathan M, Selloni A, Solowij N, Spinazzola E. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. The World Journal Of Biological Psychiatry 2022, 23: 719-742. PMID: 35315315, DOI: 10.1080/15622975.2022.2038797.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsWFSBP Task ForceRisk of psychosisAge of exposureRates of psychosisRecurrent psychosisTask ForceEndocannabinoid systemPsychosis outcomesConsensus paperHigh riskPsychotic disordersPsychotic statesPsychosisPotency of cannabisCriteria of causalityCannabisCannabinoidsLines of evidenceCannabis lawsRiskExposureDisordersEvidenceConfoundersIllnessDelta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior
Ganesh S, Cortes-Briones J, Martin A, Skosnik PD, D'Souza DC, Ranganathan M. Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior. Cannabis And Cannabinoid Research 2022, 8: 846-856. PMID: 35319274, PMCID: PMC10589482, DOI: 10.1089/can.2021.0166.Peer-Reviewed Original ResearchConceptsPsychotomimetic effectsHuman laboratory studiesDifferent dose ratiosDose-related interactionDelta-9-TetrahydrocannabinolLower CBDNeural noiseRatio-dependent mannerCannabis liberalizationHealthy volunteersElectrophysiological biomarkersMedical indicationsPsychotomimetic statesSpecific brainDose ratioPrior exposureObjective effectsHuman brainMaximal attenuationBrainTHCAntagonistic effectCannabis plantNeuroscience investigationsBehavioral responsesDorsal Column Stimulation and Cannabinoids in the Treatment of Chronic Nociceptive and Neuropathic Pain: a Review of the Clinical and Pre-clinical Data
Odonkor CA, AlFarra T, Adekoya P, Orhurhu V, Rodríguez T, Sottosanti E, Kaye AD. Dorsal Column Stimulation and Cannabinoids in the Treatment of Chronic Nociceptive and Neuropathic Pain: a Review of the Clinical and Pre-clinical Data. Current Pain And Headache Reports 2022, 26: 103-118. PMID: 35119602, DOI: 10.1007/s11916-022-01008-y.Peer-Reviewed Original ResearchMeSH KeywordsCannabinoidsChronic PainHumansNeuralgiaNociceptionQuality of LifeSpinal Cord StimulationConceptsSpinal cord stimulationNociceptive painLong-term healthcare costsPain treatment modalitiesDorsal column stimulationPre-clinical dataHigh safety profileCannabinoid-based medicationsPain-signaling pathwaysQuality of lifeMinimal side effectsOpioid consumptionNeuropathic painPain reliefAdjunctive therapySecondary outcomesPain managementCannabinoid therapyClinical efficacyCord stimulationSafety profileCombination therapyFunctional statusTreatment modalitiesFunctional capacity
2021
Risks and Benefits of Cannabis and Cannabinoids in Psychiatry
Hill KP, Gold MS, Nemeroff CB, McDonald W, Grzenda A, Widge AS, Rodriguez C, Kraguljac NV, Krystal JH, Carpenter LL. Risks and Benefits of Cannabis and Cannabinoids in Psychiatry. American Journal Of Psychiatry 2021, 179: 98-109. PMID: 34875873, DOI: 10.1176/appi.ajp.2021.21030320.Peer-Reviewed Original ResearchConceptsPsychiatric disordersRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialTherapeutic useEvidence basePlacebo-controlled trialManagement of painBenefits of cannabisSearch of PubMedMental health cliniciansCurrent evidence basePotential side effectsSpecific medical conditionsPsychiatric indicationsFDA indicationClinical trialsHealth cliniciansMedical conditionsReference listsSide effectsChronic cannabisPsychotic disordersDrug AdministrationAdditional articlesMedicinal cannabisControl of exploration, motor coordination and amphetamine sensitization by cannabinoid CB1 receptors expressed in medium spiny neurons
Bonm AV, Elezgarai I, Gremel CM, Viray K, Bamford NS, Palmiter RD, Grandes P, Lovinger DM, Stella N. Control of exploration, motor coordination and amphetamine sensitization by cannabinoid CB1 receptors expressed in medium spiny neurons. European Journal Of Neuroscience 2021, 54: 4934-4952. PMID: 34216157, PMCID: PMC9377695, DOI: 10.1111/ejn.15381.Peer-Reviewed Original ResearchMeSH KeywordsAmphetamineAnimalsCannabinoidsCorpus StriatumMiceMice, KnockoutNeuronsReceptor, Cannabinoid, CB1ConceptsMedium spiny neuronsR KO miceAmphetamine sensitizationKO miceMotor coordinationSpiny neuronsImpaired motor coordinationInvolvement of CBCannabinoid 1 receptorCannabinoid CB1 receptorsCB1 receptorsNeuronal subpopulationsCannabimimetic responsesInhibitory neuronsSpontaneous locomotionR activationR expressionMiceMouse linesKnockout backgroundNeuronsSpecific CBNew functional roleSensitizationDifferent behavioral responsesShould You Recommend Cannabinoids for This Patient With Painful Neuropathy? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Smetana GW, Tetrault JM, Hill KP, Burns RB. Should You Recommend Cannabinoids for This Patient With Painful Neuropathy? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Annals Of Internal Medicine 2021, 174: 237-246. PMID: 33556279, DOI: 10.7326/m20-7945.Peer-Reviewed Original ResearchConceptsNeuropathic painChronic painBeth Israel Deaconess Medical CenterPlacebo-treated patientsChronic neuropathic painPainful diabetic neuropathyPotential therapeutic effectsPrimary care practicesEvidence Review GroupEffects of cannabisNoncancer painPainful neuropathyDiabetic neuropathyTherapeutic effectMedical CenterGeneral internistsPainMedical cannabisReview GroupPatientsCare practicesSystematic reviewAddiction medicineCBD productsPatient interest
2020
Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use
Koch CD, Xu L, Curtis SA, Roberts JD, Bunch DR, El-Khoury JM. Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use. Clinica Chimica Acta 2020, 510: 515-521. PMID: 32795544, DOI: 10.1016/j.cca.2020.08.014.Peer-Reviewed Original ResearchConceptsCannabis useUrine samplesLoss of appetiteMinor cannabinoidsRapid LC-MS/MSDronabinol groupDronabinol therapyDronabinol useSevere nauseaPain managementPositive subjectsNormal controlsTherapeutic potentialProspective sampleClinical urine samplesCancer chemotherapySpecific populationsCannabisCannabinoidsMetabolite concentrationsDronabinolLC-MS/MSNegative controlDetection of cannabisCannabidiolCannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity
Gibson CL, Bassir Nia A, Spriggs SA, DeFrancisco D, Swift A, Perkel C, Zhong X, Mazumdar M, Fernandez N, Patel M, Kim-Schulze S, Hurd YL. Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity. Psychiatry Research 2020, 293: 113380. PMID: 32818918, PMCID: PMC8292796, DOI: 10.1016/j.psychres.2020.113380.Peer-Reviewed Original ResearchConceptsInterleukin-6Psychosis severityCannabinoid useCannabis useIL-6 levelsCommon underlying pathologyPANSS total scoreChronic psychotic disordersRisk of psychosisPsychiatric emergency roomNegative Syndrome ScalePsychotic symptom severityInflammatory alterationsInflammatory markersInflammatory disturbancesAcute psychosisInflammatory abnormalitiesNata medicationUnderlying pathologyEmergency roomInflammatory levelsPANSS scoresPsychiatric unitUnadjusted modelsPsychotic disordersIn an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers
Schindler EAD, Schnakenberg Martin AM, Sewell RA, Ranganathan M, DeForest A, Pittman BP, Perrino A, D’Souza D. In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers. Psychopharmacology 2020, 237: 3097-3107. PMID: 32632491, DOI: 10.1007/s00213-020-05595-9.Peer-Reviewed Original ResearchConceptsCapsaicin-induced hyperalgesiaCross-over studyHealthy human subjectsIntravenous THCAcute painAntinociceptive effectDrug effectsDrug AdministrationHuman subjectsDose-related mannerPeak drug effectHealthy human volunteersSignificant antinociceptive propertiesRationaleAnimal studiesElectrical painPain conditionsPain managementChemical painPain ratingsAntinociceptive propertiesHealthy volunteersPsychoactive dosesAcute chemicalHuman studiesCognitive alterationsCannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation
Liu C, Sadat S, Ebisumoto K, Sakai A, Panuganti B, Ren S, Goto Y, Haft S, Fukusumi T, Ando M, Saito Y, Guo T, Tamayo P, Yeerna H, Kim W, Hubbard J, Sharabi A, Gutkind J, Califano J. Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation. Clinical Cancer Research 2020, 26: 2693-2703. PMID: 31932491, PMCID: PMC7538010, DOI: 10.1158/1078-0432.ccr-18-3301.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisCannabinoidsCell MovementCell ProliferationFemaleHead and Neck NeoplasmsHumansMiceMice, Nudep38 Mitogen-Activated Protein KinasesPapillomaviridaePapillomavirus InfectionsPrognosisReceptors, CannabinoidSquamous Cell Carcinoma of Head and NeckTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsHead and neck squamous cell carcinomaHPV-positive head and neck squamous cell carcinomaHPV-positive HNSCC cell linesNeck squamous cell carcinomaHNSCC cell linesSingle-sample gene set enrichment analysisSquamous cell carcinomaP38 MAPK pathway activationHNSCC cohortCell carcinomaMAPK pathway activationHPV-negative head and neck squamous cell carcinomaHuman papillomavirus (HPV)-related headCell linesAnimal modelsCannabinoid receptor activationHPV- HNSCC patientsHead and neck squamous cell carcinomas dataMarijuana usePathway activationDaily marijuana useWhole-genome expression analysisCannabinoid exposureHNSCC patientsP38 MAPK activation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply